AI-Native Scoping Reviews & Evidence Mapping

PSV is not just a number for grading carotid stenosis—it can signal restenosis risk, hemodynamic compromise, plaque instability, and response to revascularization, but only when interpreted in the right anatomical and technical context. Read the full paper to see where PSV truly adds clinical value, where it can mislead, and how the evidence supports smarter carotid ultrasound decision-making.

This paper shows that carotid stenosis is not a rare incidental finding but a patterned disease concentrated in stroke, TIA, and clearly defined high-risk groups—while broad screening in low-yield populations adds little. It is worth reading because it maps where carotid imaging truly matters and why future risk assessment may need to move beyond percent narrowing toward plaque vulnerability.

Carotid stenosis outcomes are not determined by narrowing alone: this review shows how symptom status, procedure choice, restenosis, and plaque vulnerability markers can decisively shift stroke risk and long-term prognosis. Read the full paper to see which patients appear to benefit from intervention, where CEA and CAS truly diverge, and why modern risk stratification may need to move beyond luminal stenosis.

This paper shows that in carotid stenosis, the real difference is not only who gets operated on, but who receives and continues the right medical therapy. It is worth reading because it identifies the medication strategies that most consistently align with better outcomes and exposes adherence as a major, underappreciated driver of prognosis.

This paper shows that carotid stenosis is not just a problem of how narrow the artery looks: inflammation repeatedly emerges as the hidden biology that helps explain which plaques become dangerous, embolize, and lead to recurrent stroke. The full review is worth reading because it maps where PET imaging, blood biomarkers, and anti-inflammatory strategies may move carotid care beyond stenosis grading alone toward a more precise, risk-based treatment model.

This paper shows that CT angiography in carotid stenosis is not just about measuring narrowing: it can reveal plaque vulnerability, near-occlusion, carotid webs, and hidden stroke risk that standard stenosis thresholds may miss. It is worth reading because it maps where CT truly adds clinical value, where it can mislead, and how more structured CTA reporting could change decision-making.

This paper shows that carotid shunts are neither universally protective nor universally harmful: they can reduce stroke risk in selected high-risk carotid surgery patients, but they also introduce their own complications. It is worth reading because it maps when shunting may truly help, when it may be unnecessary, and how monitoring can guide a safer, more tailored surgical strategy.

This paper shows that carotid-related stroke is not primarily a story of narrowing alone, but of vulnerable plaque biology, hidden high-risk lesions, and smarter individualized selection between medical therapy, surgery, and stenting. The full review is worth reading because it maps where modern carotid care is genuinely shifting, from stenosis percentage toward plaque-driven, multimodal stroke risk stratification.

Blue toe syndrome is not just a toe finding — it is a warning signal for distal microembolization, systemic vascular risk, and hidden hematologic, autoimmune, malignant, procedural, or mechanical causes. This SAIMSARA evidence map turns scattered case-level and cohort evidence into a structured diagnostic and treatment roadmap for clinicians and AI agents needing citation-linked BTS reasoning.

This review maps 29 original studies comparing barefoot, minimalist, mobility, and conventional footwear across gait biomechanics, foot morphology, stability, knee loading, and performance. It shows where barefoot-like footwear may be useful — fall-risk stability, intrinsic foot strength, and knee OA load reduction — and where conventional shoes still matter, especially for impact moderation and postoperative walking capacity.

This review turns 1,815 original studies and 919,224 participants into a structured evidence map showing when barefoot walking/running may improve mechanics, balance, foot strength, or knee loading — and when it becomes clinically risky. It is especially useful for clinicians, runners, coaches, and researchers who need a clear, citation-linked map of barefoot biomechanics, diabetic-foot risk, falls, infection exposure, and safe transition strategies.

The main message of this paper is that current treatment of atherosclerosis relies mainly on standard preventive therapies—cholesterol lowering, combination lipid therapy, and blood-pressure control—whereas future treatment may come from more precise targeting of inflammation, endothelial injury, oxidative stress, immune pathways, and plaque biology. The review maps 47 original research topics, from combination therapies to cannabinoid receptor modulation, and 10 recurrent directions in the non-original literature, from lipid reduction to personalized imaging of plaque burden.